ACEi, angiotensin II converting enzyme inhibitor; ARB, angiotensin II-receptor blocker; CKD, chronic kidney disease; CPS, calcium polystyrene sulfonate; ESRD, end-stage renal disease; eGFR, estimated glomerular filtration rate; GI, gastrointestinal; HK, hyperkalaemia; IDNT, Irbesartan Diabetic Nephropathy Trial; K+, potassium ions; MRA, mineralocorticoid-receptor antagonist; Na+, sodium ions; NIDDM, non-insulin-dependent diabetes mellitus; RENAAL, Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan; RAASi, renin−angiotensin−aldosterone system inhibitors; RR, relative risk; SPS, sodium polystyrene sulfonate; T2DM, type 2 diabetes mellitus; US, United States.
References:
1. Rosano GMC, et al. Eur Heart J Cardiovasc Pharmacother 2018;4(3):180−8. 2. Epstein M, et al. Am J Manag Care 2015;21(11 Suppl):S212−S220. 3. Yildirim T, et al. Ren Fail 2012;34(9):1095−9. 4. KDIGO Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int 2020;98(Suppl 4S):S1–S116. 5. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3:1–150. 6. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. 2004. Available at: kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_bp/index.htm (accessed July 2020). 7. National Institute for Health and Care Excellence. Chronic kidney disease in adults: assessment and management. 2014. Available at: http://www.nice.org.uk/CG182 (accessed April 2020). 8. Lewis EJ, et al. N Engl J Med 2001;345(12):851−60. 9. Brenner BM, et al. N Engl J Med 2001;345(12):861−9. 10. The GISEN Group. Lancet 1997;28;349(9069):1857−63. 11. Palmer BF. N Engl J Med 2004;351(6):585−92. 12. Georgianos PI, Agarwal R. Kidney Int 2018;93(2):325−34. 13. Nilsson E, et al. Int J Cardiol 2017;245:277−84. 14. Einhorn LM, et al. Arch Intern Med 2009;169(12):1156−62. 15. Bandak G, et al. J Am Heart Assoc 2017;6(7):e005428. 16. Qiao Y, et al. JAMA Intern Med 2020;180(5):718−26. 17. Dunn JD, et al. Am J Manag Care. 2015;21(15 Suppl):S307−S315. 18. National Kidney Foundation. The DASH Diet. Available at: kidney.org/atoz/content/Dash_Diet (accessed July 2020). 19. Palmer SC, et al. Cochrane Database Syst Rev 2017;4:CD011998. 20. Vendramini LC, et al. Braz J Med Biol Res 2012;45(9):834−40. 21. Ishikawa S, et al. PLOS One 2018;13:1–16. 22. Calcium Resonium PI. Sanofi 2018. 23. Kayexalate® US PI. Sanofi 2017.